Surgical resection of upper gastro-intestinal malignancies carries substantial morbidity and mortality. In many cases, these cancers are thought to be resectable until the phase of laparotomy, at which time widespread or metastatic disease is revealed, preventing resection  .
The potential to avert a non-therapeutic laparotomy by means of precise and less aggressive staging is the pouring force behind laparoscopic staging of upper gastrointestinal malignancies.  Laparoscopy can play a complementary role in the pre-operative radiological examination in the precise staging of abdominal malignancies  .
Precise staging supports in the suitable management choice for cure or palliation. Furthermore, research concerning neo-adjuvant protocols for locally advanced cancers makes accurate staging bossy.  Laparoscopic analysis can envisage the primary tumor, recognize hepatic metastases, detect regional nodal metastases and perceive small-volume peritoneal disease unnoticed by other non-invasive staging modalities, such as computerized tomography (CT), magnetic resonance imaging (MRI), or ultrasonography (US). The technique also eases obtaining biopsy specimens and aspiration cytology.  Laparoscopic ultrasound (LUS) can be used to assess deep organ parts that are not open to inspection, and can perceive hepatic metastases not noticed by the conventional pre-operative imaging such as US and CT   .
Sometimes, palliative measures such as laparoscopic gastric bypass for gastric outlet obstruction and laparoscopic celiac plexus block to treat stubborn pain from upper abdominal malignancies can be achieved   .
2. Aim of the Work
To assess the starring role of laparoscopy and LUS in:
1) Correct staging of upper gastro-intestinal malignant tumors [lower esophageal, gastric and peri-pancreatic (pancreatic head, peri-ampulary or distal common bile duct) carcinomas].
2) Potential palliation in advanced patients for pain (by neurolytic celiac ple- xus block) or gastric outlet obstruction (by laparoscopic bypass surgery).
3. Patients and Methods
This study was completed in the National Cancer Institute, Cairo University. 62 patients with pathologically confirmed either lower esophageal, gastric or peri- pancreatic malignancies were joined in the study.
All patients were candidates for proper staging using laparoscopy and LUS. Laparoscopic assisted biopsies were taken from any doubtful hepatic deposits, nodal metastasis or peritoneal deposits. Peritoneal fluid cytology or peritoneal wash were done in every case.
Data collected during laparoscopic staging were reviewed during open surgery in operable cases. Advanced and metastatic cases were candidates for laparoscopic palliation in the form gastric bypass in gastric outlet obstruction or celiac plexus block (CPB) in subjects with stubborn abdominal pain, particularly cases with advanced pancreatic carcinomas.
3.1. Inclusion Criteria
Patients with no contraindications for laparoscopy, no sepsis or active general infection, stage I, II, and III lower esophageal, gastric and peri-pancreatic carcinomas (for correct staging), cases with stage IV (for appropriate staging and probable palliation), and cases received neo-adjuvant chemotherapy or radiotherapy (to estimate the outcome of the management).
3.2. Exclusion Criteria
Patients who were unfit for surgery, or patients rejecting diagnostic laparoscopy, were excluded from the study. Patients with stage IV disease not pliable for palliation (not complaining of pain or appearance of gastric outlet obstruction) were also excluded, since there would be no symptoms we would be able to palliate.
All patients were subjected to history taking, physical examination, serum laboratory tests included; CBC, coagulation profile, full liver profile, renal profile and CEA, CA.19.9 as tumor markers), radiological investigations included; pelvi-abdominal CT and chest CT scan for exploration of the primary tumor and as metastatic work up, upper GI endoscopy and biopsy in lower esophageal and gastric carcinoma, ERCP and possible biliary stenting in peri-pancreatic carcinoma with malignant obstructive jaundice.
This study comprised 62 patients with upper gastrointestinal malignancies, 41 (66%) males and 21 (34%) females with mean age 56.1 ± 4.1 years. Patients were further divided into 5 subgroups; 21 cases (33.9%) with gastric carcinoma, 12 cases (19.4%) with lower esophageal carcinoma, 12 cases (19.4%) with pancreatic head carcinoma, 10 cases (16.3%) with peri-ampullary carcinoma and 7 cases (11.3%) with common bile duct (CBD) carcinoma.
Pre-operative CT scan (Figure 1) chest was completed in every subject and was free of metastatic deposits; tumor markers (CEA, CA19.9) were prepared in selected cases; and routine pre-operative examinations were normal in all cases. All data collected during staging laparoscopy (SL) were established after exploration of operable cases and were correct except in only 4 cases giving SL and LUS procedure specificity (77.8%), positive predictive value (91.8%), sensitivity (100%) and (100%) negative predictive value.
In these four cases the SMV was encased and invaded in one case of pancreatic carcinoma and one case of distal CBD carcinoma. The other two cases of gastric carcinomas showed fixed celiac and porta-hepatis nodes and one of them showed also para-aortic nodes, and a palliative gastrectomy was performed.
Peritoneal wash and cytology was completed in all cases without ascitis (53 cases, 85.5%) and all of them were negative for malignant cells, ascitic fluid cytology was taken in 9 cases and was positive for malignancy, nodal biopsy was taken in 8 cases and was positive, peritoneal biopsy in one case and was positive, omental biopsy in one case and was positive and liver biopsy from one case and was negative.
After diagnostic laparoscopy (DL), 14 (22.5%) cases were inoperable and protected from unnecessary laparotomies and 48 (77.5%) were operable. The established criteria of inoperability were; ascitis in 9 cases (14.5%), nodal deposits in 8 cases (12.9%), liver deposits in 5 cases (8.1%), peritoneal deposits in one case (1.6%) (Figure 2) and omental nodule in one case (1.6%). Collective criteria were found in numerous of these inoperable cases.
Palliative management was done in only four cases (6.5%); laparoscopic CPB in two cases, laparoscopic gastro-jujenstomy in one case and palliative laparoscopic gastrectomy and gastro-jujenstomy in one case.
The average hospital stay was two days for all subjects of DL only with 45 minutes (+/−10 minutes) operational time. Minor complications were met in only 3 cases (4.8%). One case with laparoscopic CPB complicated with transient post- operative hypotension, which was adjusted with intra-venous fluids, the second case with laparoscopic CPB complicated with self-limiting diarrhea for one day with transient hypotension, and the third case with laparoscopic gastro-jeju- nostomy was complicated by post-operative vomiting for 2 days, which fixed by conservative treatment.
After SL, 6 cases were operable, one of them displayed small hepatic focal lesion in segment 2 and laparoscopic liver biopsy was performed and frozen section examination revealed bile duct hamartoma. One case was inoperable and showed 3 hepatic focal lesions, porta-hepatisand celiac nodes and mild ascitis (aspiration cytology was taken).
Figure 1. Pre-operative CT scan of gastric carcinoma case without ascites or peritoneal deposit.
Figure 2. Peritoneal deposit in gastric carcinoma case after DL.
As other invasive analytical measures, SL should be only accomplished when there are no accessible non-invasive staging methods with comparable or equivalent data.  Diagnostic profit and the data delivered by SL is essential and capable of altering the management plan, depending on SL results; so therapeutic decisions should be reserved by oncologic multidisciplinary commands and the treatment alternatives, should be obviously specified.
In our work we used LUS shared with standard DL in all our patients to get the full advantage from the technique. The information collected during staging laparoscopy SL were established after examination of operable cases and were accurate except in only 4 out of 62 cases, giving staging laparoscopy and LUS procedure specificity (77.8%), positive predictive value (91.8), sensitivity (100%) and (100%) negative predictive value.
Other studies have appraised the additive advantage of laparoscopic US at the period of laparoscopic staging. In a cohort of 90 subjects with pancreatic cancer, laparoscopic US concluded the resectability in 13 patients (14%), where laparoscopic analysis alone had led to vagueresults  .
The mutual use of laparoscopy and laparoscopic US confirmed a positive predictive index of 100%, negative predictive index of 98% and accuracy of 98%.  Moreover, Hunerbein et al.  stated that laparoscopic US added additional data to laparoscopy in 12% of subjects with pancreatic cancer, who were establish to have resectable disease on preoperative US, CT and MRI. The mixture of SL with US in this work confirmed irresectability in 57% of cases with a consequential change in surgical plan. In our series, 14 patients (22.5%) were inoperable and protected from needless laparotomy after DL, and 48 subjects (77.5%) were operable.
In a series from the Memorial Sloan-Kettering Cancer Center of 115 patients who were all thought resectable based on pre-operative imaging, laparoscopy recognized 41 (36%) patients with irresectable disease who were saved laparotomy. Additionally, the extended laparoscopy technique that the authors of this study used predicted resectability in 92% of subjects  .
In another study from the Massachusetts General Hospital that included 125 pancreatic cancer patients who had experienced spiral CT for valuation of resectability, SL recognized 31% of patients with unsuspected incurable disease and saved them the morbidity of laparotomy. The sensitivity of SL was calculated at 97% and the specificity at 100%  .
Further evidence on the importance of SL comes from a recent study of 84 patients with resectable pancreatic cancer based on preoperative helical CT scan. In this cohort study, staging laparoscopy revealed unpredicted CT-occult metastases in 31% of patients who were spared laparotomy  .
The established criteria of inoperability in our series were; ascitis in 9 cases (14.5%), nodal deposits in 8 cases (12.9%), liver deposits in 5 cases (8.1%), peritoneal deposits in one case (1.6%) and omental nodule in one case (1.6%). Mutual criteriaoccurred in many of these inoperable cases. Warshaw  revealed that small hepatic or peritoneal embeds could be noticed with substantial precision by standard laparoscopy.
In our series, peritoneal wash and cytology was completed in all cases without ascitis; 53 cases (85.5%) and all of them were negative for malignant cells.
Jimenez et al.  described a 7% rate of positive peritoneal cytology as the only confirmation of metastatic disease during laparoscopy in 125 subjects considered resectable by pre-operative CT scan. The same authors described a 14% rate of positive peritoneal cytology in the lack of evident metastasis in a larger number of subjects (n = 239)  .
Moreover, most studies propose that pancreatic cancer cases with positive peritoneal cytology have comparable outcomes to cases with metastatic disease; this is reproduced in the 6th edition of the American Joint Commission on Cancer (AJCC) Cancer Staging Manual, which describes positive peritoneal cytology as M1 disease  .
So the role of peritoneal wash cytology as auxiliary tool to SL is still debatable taking in attention the low profit of the procedure, elongation of the duration of the technique and cost benefit. In our study, minor complications were met in only 3 cases (4.8%), all of them were exposed to palliative management. The other cases with only DL technique showed uneventful post-operative course.
Regardless of the technological improvements of imaging modalities, yet, recent series stay to document a high incidence of irresectability found at the time of surgery. Low volume metastatic disease and retroperitoneal vascular invasion impeding curative resection are the main causes for the letdown of non-invasive imaging modalities in expecting resectability. The role of laparoscopic staging lies in recognizing those cases with imaging occult irresectable disease, and thus in avoiding the morbidity of avoidable laparotomies. Laparoscopic US, and to a lesser extent peritoneal cytology, done at the time of SL, expands its diagnostic precision by letting the identification of irresectable disease (deep hepatic metastases or vascular invasion) overlooked by visual inspection alone.
Staging laparoscopy is clearly helpful for a percentage of cases with upper gastro-intestinal carcinomas and designated in all cases with vague results on preoperative imaging and tumor size more than T1. We were able to show that DL might help us to avoid needless laparotomy in 22.5% of patients, avoiding its post-operative complications and reducing post-operative hospital stay and cost.
DL might also help us to accomplish palliative management for the advanced cases, either in the form of palliative resection or bypass or palliative laparoscopic celiac plexus block.
We recommend the use of DL as a safe, effective and complimentary method to the other tedious imaging modalities, in correct staging and probable palliation for upper gastrointestinal malignancies.
 Chang, L., Stefanidis, D., Richardson, W.S., Earle, D.B. and Fanelli, R.D. (2009) The Role of Staging Laparoscopy for Intra Abdominal Cancers: An Evidence Based Review. Surgical Endoscopy, 23, 231-241.
 Nieveen van Dijkum, E.J., de Wit, L.T., van Delden, O.M., Rauws, E.A., van Lanschot, J.J., Obertop, H., et al. (1997) The Efficacy of Laparoscopic Staging in Patients with Upper Gastrointestinal Tumors. Cancer, 79, 1315-1319.
 Clements, D.M., Bowrey, D.J. and Havard, T.J. (2004) The Role of Staging Investigations for Oesophago-Gastric Carcinoma. European Journal of Surgical Oncology, 30, 309-312.
 Luque-de Leon, E., Tsiotos, G.G., Balsiger, B., Barnwell, J., Burgart, L.J. and Sarr, M.G. (1999) Staging Laparoscopy for Pancreatic Cancer Should Be Used to Select the Best Means of Palliation and Not Only to Maximize the Resectability Rate. Journal of Gastrointestinal Surgery, 3, 111-117.
 Conlon, K.C., Doughtery, E., Klimstra, D.S., Coit, D.G., Turnbull, A.D. and Brennan, M.F. (1996) The Value of Minimal Access Surgery in the Staging of Patients with Potentially Resectable Peripancreatic Malignancy. Annals of Surgery, 223, 134-140.
 Yan, B.M. and Myers, R.P. (2007) Neurolytic Celiac Plexus Block for Pain Control in Unresectable Pancreatic Cancer. The American Journal of Gastroenterology, 102, 430-438.
 Minnard, E.A., Conlon, K.C., Hoos, A., Dougherty, E.C., Hann, L.E. and Brennan, M.F. (1998) Laparoscopic Ultrasound Enhances Standard Laparoscopy in the Staging of Pancreatic Cancer. Annals of Surgery, 228, 182-187.
 Jimenez, R.E., Warshaw, A.L., Rattner, D.W., Willett, C.G., McGrath, D. and Fernandez-del Castillo, C. (2000) Impact of Laparoscopic Staging in the Treatment of Pancreatic Cancer. Archives of Surgery, 135, 409-414.
 Vollmer, C.M., Drebin, J.A., Middleton, W.D., Teefey, S.A., Linehan, D.C., Soper, N.J., et al. (2002) Utility of Staging Laparoscopy in Subsets of Peripancreatic and Biliary Malignancies. Annals of Surgery, 235, 1-7.
 Jimenez, R.E., Warshaw, A.L. and Fernandez-Del Castillo, C. (2000) Laparoscopy and Peritoneal Cytology in the Staging of Pancreatic Cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 7, 15-20.
 American Joint Commission on Cancer (2002) Exocrine Pancreas. In Greene, F.L., Page, D.L., Fleming, I.D., Fritz, A.G., Balch, C.M., Haller, D.G., et al., Eds., AJCC Cancer Staging Manual, 6th Edition, Springer-Verlag, New York, 157-164.